Skip to main content
SpringerLink
Log in

Dose Response Evaluation

Use of Plasma Concentration Confidence Intervals as a Tool to Predict Optimal Drug Dose Ratio

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Conclusion

This paper suggests that pharmacokinetic data might provide a rational basis to improve dose-response trials. Construction of plasma concentration confidence intervals may be a tool to predict optimal drug dose ratios for dose-response studies and, for some drugs, may point to the need for plasma concentration measurement in clinical practice. An important task now is to integrate pharmacokinetic knowledge into the design of clinical trials. To facilitate this, studies on clinical pharmacokinetics should report individual plasma AUC or clearance values or give the 95% confidence intervals of the observation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bonneterre J, Coppens H, Mauriac L, Metz M, Rousse J, et al. Aminoglutethimide in advanced breast cancer. Clinical results of a French multicenter randomized trial comparing 500mg and 1g per day. European Journal of Cancer and Clinical Oncology 21: 1153–1158, 1985

    Article  CAS  Google Scholar 

  • Bruning PF, Bonfrer JMG, Hart AAM, van der Linden E, de Jong-Bakker M, et al. Low dose aminoglutethimide without hydro-cortisone for the treatment of advanced postmenopausal breast cancer. European Journal of Cancer and Clinical Oncology 25: 369–376, 1989

    Article  CAS  Google Scholar 

  • Gallagher CJ, Cairnduff F, Smith IE. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. European Journal of Cancer and Clinical Oncology 23: 1895–1900, 1987

    Article  CAS  Google Scholar 

  • Glantz SA. Primer of biostatistics, 2nd ed., McGraw-Hill Book Company, New York, 1987

    Google Scholar 

  • Hodges JL, Lehmann EL. Basic concepts of probability and statistics, Holden Day Inc., San Francisco, 1970

    Google Scholar 

  • Johnson RA, Wichern DW. Applied multivariate analysis, Prentice-Hall Inc., Englewood Cliffs, NJ, 1982

    Google Scholar 

  • Lindgren BW. Statistical theory, MacMillan Company, London, 1962

    Google Scholar 

  • Lønning PE. Aromatse inhibition: past, present and future. In Dousett M (Ed.) Endocrine aspects of breast cancer, pp. 53–75, Parthenon Publishing Group, Carnforth, 1992

    Google Scholar 

  • Lønning PE, Schanche JS, Kvinnsland S, Ueland PM. Single-dose and steady-state pharmacokinetics of aminoglutethimide. Clinical Pharmacokinetics 10: 353–364, 1985

    Article  PubMed  Google Scholar 

  • Newell DR. Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. British Journal of Cancer 61: 189–191, 1990

    Article  PubMed  CAS  Google Scholar 

  • Robustelli della Cuna G. 500mg versus 1000mg aminoglutethimide (AG) in advanced breast cancer: 3 years results of an Italian multicentre trial. European Journal of Cancer 27 (Suppl. 2): s69, 1991

    Google Scholar 

  • Rosner B. Fundamentals of biostatistics, Duxbury Press, Boston, 1982

    Google Scholar 

  • Simon RM. Design and conduct of clinical trials. In DeVita Jr VT et al. (Eds) Cancer — principles and practice of oncology, pp. 329–350, J.B. Lippincott Company, Philadelphia, 1985

    Google Scholar 

  • Spiegel MR. Probability and statistics, McGraw-Hill Book Company, New York, 1975

    Google Scholar 

  • Strocchi E, Camaggi CM, Martoni A, Cellerino R, Miseria S, et al. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. Cancer Chemotherapy and Pharmacology 27: 451–455, 1991

    Article  PubMed  CAS  Google Scholar 

  • van Veelen H, Wilemse PHB, Sleijfer DT, Sluiter WJ, Doorenbos H. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treatment Reports 69: 977–983, 1985

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Haukeland University Hospital, N-5021 Haukeland Sykehus, Bergen, Norway

    Per Eystein Lønning

  2. University of Bergen, Bergen, Norway

    Per Eystein Lønning

Authors
  1. Per Eystein Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lønning, P.E. Dose Response Evaluation. Clin. Pharmacokinet. 25, 1–5 (1993). https://doi.org/10.2165/00003088-199325010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325010-00001

Keywords

Search

Navigation